Insider Buying: Cytosorbents Co. (NASDAQ:CTSO) COO Buys 5,000 Shares of Stock

Cytosorbents Co. (NASDAQ:CTSOGet Rating) COO Vincent Capponi purchased 5,000 shares of Cytosorbents stock in a transaction dated Monday, May 23rd. The stock was bought at an average cost of $2.03 per share, with a total value of $10,150.00. Following the completion of the transaction, the chief operating officer now owns 438,545 shares in the company, valued at approximately $890,246.35. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Cytosorbents stock traded up $0.02 during trading hours on Wednesday, hitting $1.89. 151,366 shares of the stock traded hands, compared to its average volume of 211,913. The firm’s 50 day moving average price is $2.62 and its 200-day moving average price is $3.68. The stock has a market capitalization of $82.33 million, a price-to-earnings ratio of -2.78 and a beta of 0.48. Cytosorbents Co. has a 1 year low of $1.78 and a 1 year high of $9.80.

Cytosorbents (NASDAQ:CTSOGet Rating) last posted its quarterly earnings results on Tuesday, May 3rd. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.06). Cytosorbents had a negative net margin of 71.16% and a negative return on equity of 44.65%. During the same period in the previous year, the company posted ($0.10) EPS. Sell-side analysts expect that Cytosorbents Co. will post -0.63 earnings per share for the current year.

Several research analysts have recently commented on CTSO shares. B. Riley reduced their price target on Cytosorbents from $7.00 to $6.00 in a research report on Wednesday, May 4th. StockNews.com initiated coverage on Cytosorbents in a research note on Thursday, March 31st. They set a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, Cytosorbents currently has an average rating of “Buy” and a consensus target price of $9.67.

Institutional investors and hedge funds have recently modified their holdings of the company. Chicago Partners Investment Group LLC purchased a new stake in shares of Cytosorbents in the first quarter worth about $28,000. Marshall Wace LLP acquired a new position in Cytosorbents in the 4th quarter worth about $31,000. Citigroup Inc. raised its holdings in Cytosorbents by 152.0% in the 3rd quarter. Citigroup Inc. now owns 4,945 shares of the medical research company’s stock worth $40,000 after purchasing an additional 2,983 shares during the period. Virtu Financial LLC acquired a new position in Cytosorbents in the 4th quarter worth about $46,000. Finally, Cowen Prime Advisors LLC raised its holdings in Cytosorbents by 316.0% in the 1st quarter. Cowen Prime Advisors LLC now owns 15,600 shares of the medical research company’s stock worth $50,000 after purchasing an additional 11,850 shares during the period. Hedge funds and other institutional investors own 40.98% of the company’s stock.

About Cytosorbents (Get Rating)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.

Further Reading

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.